Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046104 | 0.95 | CYP4A11 (0.56) | CYP4A11CYP4F2POLBPTPN11MAPT | |
| SCHEMBL3458276 | 0.90 | PTPN11 (0.51) | CYP4A11CYP4F2POLBPTPN11MAPT | |
| SCHEMBL22032169 | 0.84 | GABRA1 (0.46) | CYP4A11CYP4F2PTPN11GABRPGABRD | |
| SCHEMBL4990465 | 0.83 | MMP2 (0.54) | CYP4A11CYP4F2POLBPTPN11MAPT | |
| SCHEMBL16799629 | 0.82 | CYP4A11 (0.55) | CYP4A11CYP4F2POLBPTPN11PTPN2 | |
| SCHEMBL31753430 | 0.82 | CYP4A11 (0.55) | CYP4A11CYP4F2POLBPTPN11PTPN2 | |
| SCHEMBL2402609 | 0.81 | MMP2 (0.59) | PTPN11MAPTMMP2MMP12PTPN2 | |
| SCHEMBL22906952 | 0.81 | PTPN11 (0.40) | CYP4A11PTPN11GABRPGABRDGABRA1 | |
| SCHEMBL1314738 | 0.80 | MMP2 (0.49) | PTPN11GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16182177 | 0.80 | PTPN11 (0.54) | CYP4A11PTPN11MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692061-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | Aevis Bio, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024205319-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | 주식회사 아이비스바이오 | 2024-10-03 | — | — | WO | disclosed |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2023-03-23 | — | — | US | disclosed |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY | 2021-02-18 | — | — | US | disclosed |
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-10793573-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-10-06 | — | — | US | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2011143106-A1 | BI - FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-0314280-B1 | Process for the preparation of fused pyridine compounds | UNIV PRINCETON (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5473071-A | Process for the preparation of fused pyridine compounds | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0325343-B1 | L-glutamic acid derivatives | UNIV PRINCETON (US) | 1994-06-22 | — | — | EP | disclosed |
| US-4895946-A | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1990-01-23 | — | — | US | disclosed |
| US-4871743-A | L-glutamic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0325343-A2 | L-glutamic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0314280-A2 | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | CYP4A11 799/4885CYP4F2 39/4885POLB 2172/4885 |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | MTHFD1, SHMT1, SHMT2 | CYP4A11 799/4885CYP4F2 39/4885POLB 2172/4885 |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | CYP4A11 494/4885CYP4F2 227/4885POLB 2585/4885 |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | CYP4A11 816/4885CYP4F2 37/4885POLB 2204/4885 |
| US-10793573-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | SHMT2, MTHFD1, SHMT1 | CYP4A11 1171/4885CYP4F2 133/4885POLB 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.